CHARLOTTE, North Carolina (GenomeWeb) – At the annual meeting of the Association for Molecular Pathology here this week, representatives from NanoString Technologies and Merck Pharmaceuticals provided an update on their ongoing companion diagnostic collaboration, in which they are evaluating a gene expression-based assay, using NanoString's nCounter technology, to predict response to Merck's anti-PD1 immunotherapy Keytruda (pembrolizumab).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.